7th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Fleming Europe24 - 25 May 2011, Barcelona, Spain.
What are the new approaches to quality to achieve world-class manufacturing performance? How can you successfully introduce innovation and continual improvement into manufacturing?

Continuing pressures on life sciences manufacturing, from increased competition to regulatory requirements, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Leading Pharma companies are now looking to Lean Manufacturing and Six Sigma principles to help them boost operational efficiency and improve quality. Explore the importance of six sigma in process validation and how to successfully apply Lean approach in Quality Assurance to simplify the processes.

Discuss with leading experts, how to build a sustainable quality culture during the times of change. Understand how to apply QbD tools during method development phase to achieve robust and reliable analytical procedures. Gain critical insights & first-hand experience how to incorporate risk management thinking and practices across the entire organization.

This event will bring together senior industry quality & operational excellence experts from the Pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head of Quality Control, Sanofi Aventis, Germany
  • Senior Vice President Quality Assurance, Glenmark Pharmaceuticals, India
  • Head Operational Excellence & Lean, AstraZeneca, Sweden
  • Director Turbuhaler, AstraZeneca, Sweden
  • Quality Assurance Projects, Abbott, Italy
  • Head of Processes & Product Quality, Belupo, Croatia
  • More speakers to be announced

Key topics:

  • Explore Process Innovations for Operational Excellence
  • Enhance six sigma strategies to control costs, improve productivity and maintain compliance – how to integrate Quality & Operational Efficiency
  • Understand, how to link quality to performance
  • Reveal new approaches & tools for facilitating continuous improvement - building a sustainable quality culture and getting the right thinking across the entire organization
  • Maximize the benefits of QbD and Process understanding - best practices in QbD & PAT
  • Embrace Quality Risk Management - from theory to practice
  • Deployment of quality management for biologics - new challenges in aseptic processing of biologics
  • Understand new regulatory aspects of modern quality management and being prepared for the inspection

PLUS 3 Interactive Workshops:

  • Achieving efficiency in Quality Control
  • Application of Lean approach to Quality Assurance
  • Quality Risk Management - the new paradigm

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Regulatory Affairs, GMP Compliance, Quality by Design, PAT, Lean/Six Sigma, Lean Manufacturing, API manufacturing, Technical operations, Contract Manufacturing, Operational Excellence, Business Process Excellence, Operations, Production, Manufacturing, Supply Chain, Quality Risk Management, Qualified Person, Right First Time leaders.

For further information and registration, please visit:
http://flemingeurope.com/pharmaceuticals-conferences/europe/7th-annual-achieving-quality-process-excellence-in-the-pharmaceutical-industry

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...